912444-00-9

Hazard Information

Questions And Answer

• Abstract

  Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.
  Veliparib (ABT-888) is being investigated to treat squamous and non-squamous non-small cell lung cancer, BRCA breast cancer, triple negative breast cancer and ovarian cancer.;

• Biological activity

  Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.;

• In vitro

  Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor，which inhibits PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays，respectively.ABT-888 reduces clonogenic survival and inhibits DNA repair in H460 cells. ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells.;

• In vivo

  ABT-888 inhibits PARP in B16F10 and 9L xenograft models, thus enhancing the anticancer activity of temozolomide. The Combined with other cytotoxic agents, ABT-888 shows strong antitumor effect in MX-1 xenograft model. ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg according to the the size of tumors in A375 and Colo829 xenograft models.;

• Features

  ABT-888 enhances the effectiveness of common cancer treatments, such as radiation therapy and alkylating agents.;

• References

  https://www.abbvie.com/our-science/pipeline/veliparib.html
  https://en.wikipedia.org/wiki/Veliparib;

Spectrum Detail

Supplier

Related Products